Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.84
-0.4700-3.28%
Post-market: 13.840.00000.00%19:30 EDT
Volume:655.46K
Turnover:9.22M
Market Cap:764.58M
PE:-5.02
High:14.58
Open:14.23
Low:13.80
Close:14.31
52wk High:16.93
52wk Low:6.96
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.49
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.88
PE(LYR):-5.72

Loading ...

4D Molecular Therapeutics Price Target Raised to $33.00/Share from $29.00 by B of a Securities

Dow Jones
·
Sep 29

4D Molecular price target raised to $33 from $29 at BofA

TIPRANKS
·
Sep 29

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)

TIPRANKS
·
Sep 29

Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results

TIPRANKS
·
Sep 28

4D Molecular Therapeutics Enrolls First Patients in Phase 3 4sight Trial of 4D-150 for Diabetic Macular Edema

Reuters
·
Sep 28

4Dmt Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4Sight in Dme

THOMSON REUTERS
·
Sep 28

4D Molecular Therapeutics - First Patients Enrolled in 4Sight Phase 3 Trial for 4D-150 in Dme

THOMSON REUTERS
·
Sep 28

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of USD 22,317.75 in Common Shares

Reuters
·
Sep 23

4D Molecular Therapeutics CEO David Kirn Disposes of 58,333 Common Shares Worth $810,105.1

Reuters
·
Sep 17

Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral

MT Newswires Live
·
Sep 14

4D Molecular Therapeutics Price Target Announced at $20.00/Share by Cantor Fitzgerald

Dow Jones
·
Sep 14

4D Molecular Therapeutics Grants 96,000 Inducement RSUs to Seven New Employees

Reuters
·
Sep 12

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of 584 Common Shares for $8,176

Reuters
·
Sep 04

4D Molecular Therapeutics to Present at Wells Fargo, Cantor, Morgan Stanley Healthcare Investor Conferences

Reuters
·
Aug 25

4D Molecular Therapeutics CEO David Kirn Disposes of Common Shares Worth $1,068,651.63

Reuters
·
Aug 22

4D Molecular Therapeutics Posts Corporate Presentation Highlighting AAV Gene Therapy Pipeline Led by 4D-150 for Wet AMD, DME

Reuters
·
Aug 21

4D Molecular Therapeutics CLO Scott Bizily Disposes of Common Shares Worth $39,567.5

Reuters
·
Aug 18

B. Riley views EyePoint study miss as positive for 4D Molecular

TIPRANKS
·
Aug 18

4D Molecular Therapeutics Grants 35,200 RSUs to Five New Hires Under Inducement Award Plan

Reuters
·
Aug 15

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)

TIPRANKS
·
Aug 14